Search: WFRF:(Schachter F) >
The efficacy of imm...
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials
-
- Olofsson Bagge, Roger, 1978 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Wallenberg Centre for Molecular and Translational Medicine,Institute of Clinical Sciences, Department of Surgery
-
- Ny, Lars, 1967 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
Ascierto, P. A. (author)
-
show more...
-
Hodi, F. S. (author)
-
Larkin, J. (author)
-
Robert, C. (author)
-
Schachter, J. (author)
-
Weber, J. S. (author)
-
Long, G. V. (author)
-
van Akkooi, A. C. J. (author)
-
show less...
-
(creator_code:org_t)
- 2021-02-18
- 2021
- English.
-
In: Melanoma research. - : Ovid Technologies (Wolters Kluwer Health). - 0960-8931. ; 31:2, s. 181-185
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Nearly 10% of patients with high-risk early-stage melanoma will develop satellite or in-transit metastases (ITM), classified as stage III disease similar to lymph node metastases. The pivotal registration trials of the CTLA-4 antibody ipilimumab, and the PD-1 antibodies nivolumab and pembrolizumab, also included patients with unresectable stage III disease. However, there has been no analysis of patients with ITM, and anecdotal retrospective small series have indicated a potential lesser effect. This study aimed to identify patients with unresectable ITM within the randomized trials, and to determine response, progression-free survival and overall survival. The pivotal phase III randomized intervention trials that included melanoma patients with ITM, with or without nodal metastasis, and were treated with ipilimumab, nivolumab or pembrolizumab was identified. The datasets from each trial were then searched to identify the specific details of the investigated patient population for a pooled analysis. The primary endpoint was complete response rate. Seven trials that included stage III patients, and with accessible datasets, were identified. There was a total of 4711 patients, however, no patients with ITM could be identified, as this data was not captured by the case report forms. Evidence from prospective clinical trials on the use of immunotherapy in patients with ITM is lacking. We recommend pooling data from multiple institutions to examine efficacy of available drug therapies in this patient population, but more importantly, prospective clinical trials of locoregional treatments with or without systemic drug therapies are required.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Keyword
- immunotherapy
- in-transit metastasis
- melanoma
- Oncology
- Dermatology
- Research & Experimental Medicine
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Olofsson Bagge, ...
-
Ny, Lars, 1967
-
Ascierto, P. A.
-
Hodi, F. S.
-
Larkin, J.
-
Robert, C.
-
show more...
-
Schachter, J.
-
Weber, J. S.
-
Long, G. V.
-
van Akkooi, A. C ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Dermatology and ...
- Articles in the publication
-
Melanoma researc ...
- By the university
-
University of Gothenburg